U.S. FDA-authorized DBS indications and reported effects. (IMAGE)

Science China Press

U.S. FDA-authorized DBS indications and reported effects.

Caption

Overview of DBS targets and reported clinical effects for Parkinson’s disease, drug-resistant epilepsy, essential tremor, dystonia, and treatment-resistant obsessive-compulsive disorder. FDA regulatory status applies to specific DBS systems and labeled indications; some targets and outcomes shown remain investigational.

Abbreviations: ALIC, anterior limb of the internal capsule; ANT, anterior nucleus of the thalamus; BNST, bed nucleus of the stria terminalis; CMT, centromedian nucleus of the thalamus; CM-Pf, centromedian-parafascicular complex; cZI, caudal zona incerta; GPi, globus pallidus internus; ITP, inferior thalamic peduncle; MFB, medial forebrain bundle; MS, medial septum; NAc, nucleus accumbens; PPN, pedunculopontine nucleus; SCP, superior cerebellar peduncle; STN, subthalamic nucleus; VC/VS, ventral capsule/ventral striatum; VIM, ventral intermediate nucleus; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.

Credit

©Science Bulletin

Usage Restrictions

use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.